Anaemia Clinical Trial
Official title:
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
The objectives of this study is:
- to establish the coverage rate of weekly iron supplementation in children in
intervention schools over a period of nine months
- document any side effects of weeekly iron supplementation among children in
intervention schools over a period of nine months asses the feasibility of
incorporating the weekly iron supplementation programme into the normal school activity
in intervention schools determine the extent of acceptability and support for the iron
supplementation programme by staff at the health centre nearest to the intervention
schools
- compare the praziquantel efficacy and schistosomiasis reinfection in children in
intervention schools with that of children in control schools following the
introduction of weekely iron supplementation over a period of nine months
- determine the impact of weekly iron supplementation on haemoglobin levels of children
in intervention schools and compare with children in control schools over a period of
nine months
Iron deficiency anaemia is a common denominator for both schistosomiasis and soil
transmitted helminths. Iron deficiency appears to affect the immune response against
schistosomes and intestinal helminths. It therefore follows that correcting the iron
deficiency anaemia will improve the efficacy of anthelminthics such as praziquantel (against
schistosomiasis) and albendazol (against soil transmitted helminths) and ability of the host
immune system to resist reinfection with schistosomes and soil transmitted helminths.
The aim of this study is to identify factors necessary for a successful weekly iron
supplementation programme in schistosomiasis and soil transmitted helminths control
programmes. In addition impact of weekly iron supplementation programme n haemoglobin
levels, efficacy of praziquantel, and schistosomiasis re-infection will be studied.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05682326 -
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
|
Phase 3 | |
Completed |
NCT03400033 -
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
|
Phase 3 | |
Completed |
NCT02879305 -
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
|
Phase 3 | |
Completed |
NCT02876835 -
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
|
Phase 3 | |
Terminated |
NCT02801162 -
Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard
|
N/A | |
Completed |
NCT02288637 -
Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product
|
N/A | |
Completed |
NCT00857077 -
Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana
|
N/A | |
Completed |
NCT06080555 -
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
|
Phase 1 | |
Completed |
NCT01977573 -
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
|
Phase 2 | |
Completed |
NCT02243306 -
Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
|
Phase 1 | |
Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
Completed |
NCT00140517 -
Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance
|
N/A | |
Completed |
NCT03239522 -
Absorption and Elimination of Radiolabeled Daprodustat
|
Phase 1 | |
Completed |
NCT01376232 -
Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)
|
Phase 1 | |
Completed |
NCT02019719 -
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02969655 -
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02637102 -
The UK CAVIAR Study
|
||
Completed |
NCT01454752 -
Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition
|
N/A | |
Completed |
NCT01136850 -
Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea
|
Phase 3 | |
Completed |
NCT01085552 -
Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects
|
Phase 1 |